INVEGA SUSTENNA® Common Dosing and Administration Topics

Initiation Dosing

General – Initiation Dosing Rationale

Consistent with the INVEGA SUSTENNA® Prescribing Information:

  • The initiation regimen for INVEGA SUSTENNA® (234 mg followed by 156 mg one week later, both administered in the deltoid muscle) was designed to rapidly attain steady-state paliperidone plasma concentrations when initiating therapy without the use of oral antipsychotic supplementation. The release profile and dosing regimen of INVEGA SUSTENNA® results in sustained therapeutic concentrations. In general, overall initiation plasma levels with INVEGA SUSTENNA® were within the exposure range observed with 6-12 mg extended-release oral paliperidone. The use of the INVEGA SUSTENNA® initiation regimen allowed patients to stay in this exposure window of 6-12 mg extended-release oral paliperidone even at trough pre-dose times (Week 1 and Week 5).

For illustrative displays of this dosing scenario, please click the link(s) below.

Initiation Dosing for Schizoaffective Disorder

Standard Dosing for Schizoaffective Disorder

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

INVEGA TRINZA® for:

  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel